<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=5.0">
    <title>ç§‘ç ”æ—¥æŠ¥ - 2025-11-14</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, "Noto Sans", sans-serif, "Apple Color Emoji", "Segoe UI Emoji";
            line-height: 1.8;
            color: #2c3e50;
            background: linear-gradient(135deg, #f5f7fa 0%, #c3cfe2 100%);
            padding: 15px;
            font-size: 16px;
        }

        .container {
            max-width: 900px;
            margin: 0 auto;
            background: white;
            padding: 35px;
            border-radius: 16px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.1);
        }

        /* æ ‡é¢˜ä¼˜åŒ– */
        h1 {
            color: #1a202c;
            font-size: 2em;
            border-bottom: 4px solid #667eea;
            padding-bottom: 15px;
            margin-bottom: 25px;
            font-weight: 700;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }

        h2 {
            color: #2d3748;
            font-size: 1.5em;
            margin-top: 40px;
            margin-bottom: 20px;
            padding-left: 15px;
            border-left: 5px solid #667eea;
            font-weight: 600;
        }

        h3 {
            color: #4a5568;
            font-size: 1.25em;
            margin-top: 28px;
            margin-bottom: 14px;
            font-weight: 600;
        }

        /* åˆ†ç±»æµè§ˆæŠ˜å åŠŸèƒ½ */
        details {
            margin: 20px 0;
            border-radius: 8px;
            overflow: hidden;
        }

        details summary {
            cursor: pointer;
            padding: 15px 20px;
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            color: #2d3748;
            font-size: 1.25em;
            font-weight: 600;
            text-align: right;
            direction: rtl;
            border-right: 5px solid #667eea;
            transition: all 0.3s ease;
            list-style: none;
            user-select: none;
        }

        details summary * {
            direction: ltr;
        }

        details summary::-webkit-details-marker {
            display: none;
        }

        details summary::before {
            content: 'â–¶';
            display: inline-block;
            margin-left: 10px;
            transition: transform 0.3s ease;
            font-size: 0.8em;
        }

        details[open] summary::before {
            transform: rotate(90deg);
        }

        details summary:hover {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            box-shadow: 0 4px 12px rgba(102, 126, 234, 0.3);
        }

        details[open] summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            border-right-color: white;
        }

        details .details-content {
            padding: 20px;
            background: white;
            border: 1px solid #e9ecef;
            border-top: none;
        }

        h4 {
            color: #718096;
            font-size: 1.1em;
            margin-top: 22px;
            margin-bottom: 12px;
            font-weight: 600;
        }

        p {
            margin-bottom: 16px;
            line-height: 1.8;
        }

        blockquote {
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            border-left: 4px solid #667eea;
            padding: 18px 22px;
            margin: 22px 0;
            border-radius: 8px;
            color: #4a5568;
            font-size: 0.95em;
            box-shadow: 0 2px 8px rgba(0,0,0,0.05);
        }

        blockquote p {
            margin-bottom: 8px;
        }

        blockquote p:last-child {
            margin-bottom: 0;
        }

        blockquote em {
            font-style: normal;
            color: #718096;
            font-size: 0.9em;
        }

        blockquote a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        blockquote a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* é¡¶éƒ¨ç½²åï¼ˆå±…å³ï¼‰ */
        .powered-by-top {
            text-align: right;
            font-size: 0.85em;
            color: #718096;
            font-style: italic;
            margin: 12px 0;
            padding-right: 5px;
        }

        .powered-by-top a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        .powered-by-top a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* AI æ€»ç»“åŒºåŸŸä¼˜åŒ– */
        .ai-summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 28px;
            border-radius: 16px;
            margin: 30px 0;
            box-shadow: 0 12px 35px rgba(102, 126, 234, 0.35);
            position: relative;
            overflow: hidden;
        }

        .ai-summary::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -50%;
            width: 200%;
            height: 200%;
            background: radial-gradient(circle, rgba(255,255,255,0.1) 0%, transparent 70%);
            pointer-events: none;
        }

        .ai-summary h2 {
            color: white;
            border-left: none;
            border-right: none;
            margin-top: 0;
            margin-bottom: 18px;
            padding-left: 15px;
            padding-right: 0;
            text-align: left;
            direction: ltr;
        }

        .ai-summary h3 {
            color: #f0f0f0;
            margin-top: 18px;
            border-right: 3px solid rgba(255,255,255,0.5);
            padding-right: 12px;
            padding-left: 0;
            text-align: right;
            direction: rtl;
        }

        .ai-summary h3 * {
            direction: ltr;
        }

        .ai-summary blockquote {
            background: rgba(255,255,255,0.15);
            border-left-color: white;
            color: white;
            backdrop-filter: blur(10px);
        }

        .ai-summary p {
            color: white;
        }

        .ai-summary strong {
            color: #fff;
            font-weight: 600;
        }

        ul, ol {
            margin-left: 28px;
            margin-bottom: 18px;
        }

        li {
            margin-bottom: 12px;
            line-height: 1.8;
        }

        /* é“¾æ¥ä¼˜åŒ– */
        a {
            color: #667eea;
            text-decoration: none;
            border-bottom: 1px solid transparent;
            transition: all 0.3s ease;
            font-weight: 500;
        }

        a:hover {
            border-bottom-color: #667eea;
            color: #764ba2;
        }

        /* è¡¨æ ¼ä¼˜åŒ– */
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            box-shadow: 0 2px 12px rgba(0,0,0,0.08);
            border-radius: 10px;
            overflow: hidden;
        }

        th, td {
            border: 1px solid #e2e8f0;
            padding: 14px 18px;
            text-align: left;
        }

        th {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            font-weight: 600;
            font-size: 0.95em;
        }

        tr:nth-child(even) {
            background: #f8f9fa;
        }

        tr:hover {
            background: #e9ecef;
            transition: background 0.3s ease;
        }

        /* å…³é”®è¯ç»Ÿè®¡è¡¨æ ¼ç‰¹æ®Šæ ·å¼ï¼ˆæ›´ç´§å‡‘ï¼‰ */
        .keywords-table {
            font-size: 0.9em;
            max-width: 600px;
        }

        .keywords-table th,
        .keywords-table td {
            padding: 10px 14px;
        }

        .keywords-table th {
            font-size: 0.9em;
        }

        hr {
            border: none;
            border-top: 2px solid #e2e8f0;
            margin: 40px 0;
        }

        strong {
            color: #2d3748;
            font-weight: 600;
        }

        code {
            background: #f1f5f9;
            padding: 3px 8px;
            border-radius: 5px;
            font-family: "SF Mono", Monaco, Consolas, "Courier New", monospace;
            font-size: 0.9em;
            color: #e53e3e;
        }

        /* ç¾åŒ–æ»šåŠ¨æ¡ */
        ::-webkit-scrollbar {
            width: 8px;
            height: 8px;
        }

        ::-webkit-scrollbar-track {
            background: #f1f1f1;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb {
            background: #667eea;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb:hover {
            background: #764ba2;
        }

        /* ç§»åŠ¨ç«¯ä¼˜åŒ– */
        @media (max-width: 768px) {
            body {
                padding: 8px;
                font-size: 15px;
            }

            .container {
                padding: 22px 18px;
                border-radius: 12px;
            }

            h1 {
                font-size: 1.6em;
                padding-bottom: 12px;
                margin-bottom: 20px;
            }

            h2 {
                font-size: 1.3em;
                margin-top: 30px;
                padding-left: 12px;
            }

            h3 {
                font-size: 1.15em;
            }

            h4 {
                font-size: 1.05em;
            }

            blockquote {
                padding: 14px 16px;
                margin: 18px 0;
            }

            .ai-summary {
                padding: 20px;
                margin: 22px 0;
            }

            .ai-summary-header {
                flex-direction: column;
                align-items: flex-start;
            }

            .powered-by {
                margin-left: 0;
                margin-top: 8px;
            }

            table {
                font-size: 0.85em;
            }

            th, td {
                padding: 10px 12px;
            }

            .keywords-table {
                font-size: 0.8em;
            }

            .keywords-table th,
            .keywords-table td {
                padding: 8px 10px;
            }

            ul, ol {
                margin-left: 22px;
            }
        }

        /* è¶…å°å±å¹• */
        @media (max-width: 480px) {
            body {
                font-size: 14px;
                padding: 5px;
            }

            .container {
                padding: 18px 14px;
            }

            h1 {
                font-size: 1.4em;
            }

            h2 {
                font-size: 1.2em;
            }

            .ai-summary {
                padding: 16px;
            }

            .powered-by {
                font-size: 0.7em;
            }
        }

        /* å¹³æ»‘æ»šåŠ¨ */
        html {
            scroll-behavior: smooth;
        }

        /* æé«˜å¯ç‚¹å‡»åŒºåŸŸ */
        @media (pointer: coarse) {
            a {
                padding: 4px 0;
                display: inline-block;
            }
        }

        /* æ‰“å°ä¼˜åŒ– */
        @media print {
            body {
                background: white;
                padding: 0;
            }

            .container {
                box-shadow: none;
                max-width: 100%;
            }

            .ai-summary {
                background: #f5f5f5;
                color: black;
                box-shadow: none;
            }

            .ai-summary h2,
            .ai-summary h3,
            .ai-summary p,
            .ai-summary strong {
                color: black;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <h1>ğŸ“… Daily Report - 2025-11-14</h1>
<blockquote>
<p>ä»Šæ—¥ç­›é€‰å‡º <strong>84</strong> æ¡å†…å®¹ï¼Œæ¥è‡ª <strong>4</strong> ä¸ªæ¥æº</p>
</blockquote>
<div class="powered-by-top">Powered by <a href="https://kyplus.de" target="_blank" rel="noopener noreferrer">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai" target="_blank" rel="noopener noreferrer">Claude</a></div>

<hr />
<div class="ai-summary">
                <h2>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</h2>
                <h3>ğŸ“° å…¬ä¼—å·</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
é¦–æ¬¡å‘ç°ç™Œç»†èƒåˆ©ç”¨â€œç—›æ„Ÿç¥ç»â€è¿œç¨‹æ“æ§å…ç–«ç³»ç»Ÿï¼Œé˜»æ–­æ­¤é€šè·¯å¯å®ç°æŠ—ç™Œä¸é•‡ç—›â€œåŒèµ¢â€ï¼›AIæŠ€æœ¯åœ¨å•ç»†èƒæ•°æ®è§£é‡Šæ–¹é¢å–å¾—çªç ´æ€§è¿›å±•ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
*   <strong>è‚¿ç˜¤å…ç–«å¾®ç¯å¢ƒè°ƒæ§</strong>ï¼šè¯†åˆ«å¹¶é¶å‘ç‰¹å®šç»†èƒäºšå‹ï¼ˆå¦‚HLA-DR+è‚¿ç˜¤ç»†èƒã€PLAUR+ä¸­æ€§ç²’ç»†èƒã€CD177+ä¸­æ€§ç²’ç»†èƒã€CTCF+TANã€IL-33+å†…çš®ç»†èƒã€MMP11+æˆçº¤ç»´ç»†èƒï¼‰ä»¥æ”¹å–„å…ç–«æ²»ç–—ç–—æ•ˆæˆ–å‡è½»ç–¾ç—…æŸä¼¤ã€‚<br />
*   <strong>è‚ é“-è‚è„è½´ä¸ä»£è°¢è°ƒæ§</strong>ï¼šè§£æè‚ é“-è‚è„è½´çš„ä»£è°¢è°ƒæ§æœºåˆ¶ï¼Œä»¥åŠä»£è°¢ç‰©å¯¹å·¨å™¬ç»†èƒæåŒ–å’Œè‚¿ç˜¤çš„å½±å“ã€‚<br />
*   <strong>å•ç»†èƒä¸ç©ºé—´ç»„å­¦åº”ç”¨</strong>ï¼šæ¢ç´¢å•ç»†èƒç©ºé—´è½¬å½•ç»„å­¦åœ¨è„‘å’Œè‚ºç ”ç©¶ä¸­çš„å¹³å°æ¯”è¾ƒï¼›ç©ºé—´ä¸‰ç»„å­¦ç»˜åˆ¶å¤§è„‘å‘è‚²ä¸ç¥ç»ç‚ç—‡å›¾è°±ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
*   <strong>å¤šç»„å­¦ç»“åˆ</strong>ï¼šè¿ç”¨å•ç»†èƒã€ç©ºé—´ç»„å­¦ã€å¹²æ¹¿ç»“åˆã€æœºå™¨å­¦ä¹ ç­‰å¤šç§æŠ€æœ¯æ‰‹æ®µè¿›è¡Œæ·±åº¦åˆ†æã€‚<br />
*   <strong>AIè¾…åŠ©åˆ†æ</strong>ï¼šAIæŠ€æœ¯åœ¨å•ç»†èƒæ•°æ®è§£é‡Šæ–¹é¢å±•ç°å‡ºå·¨å¤§æ½œåŠ›ã€‚</p>
<h3>ğŸ§¬ æ•°æ®å‰æ²¿</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
CDK4/6æŠ‘åˆ¶å‰‚åœ¨ä¹³è…ºç™Œæ²»ç–—ä¸­å±•ç°å‡ºé‡å¡‘å…ç–«è‚½æ®µç»„ã€è¯±å¯¼æŒä¹…ç”Ÿé•¿åœæ»çš„æ½œåŠ›ï¼›åŒæ—¶ï¼ŒKRASå’ŒCDK4çš„è”åˆé¶å‘æ²»ç–—åœ¨èƒ°è…ºç™Œä¸­æ˜¾ç¤ºå‡ºååŒæ•ˆåº”ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- ç™Œç—‡å…ç–«é€ƒé€¸æœºåˆ¶ï¼šå¦‚6PGDæŠ‘åˆ¶ä¸å¤©ç„¶å…ç–«åº”ç­”çš„å…³è”ï¼Œä»¥åŠPD-L1å’ŒmiR-27a-3pååŒé‡å¡‘Tç»†èƒæ²»ç–—ç‚ç—‡æ€§è‚ ç—…ã€‚<br />
- ä¿¡å·é€šè·¯ä¸è€è¯æ€§ï¼šOxr1å¤±è°ƒåœ¨æ…¢æ€§é«“ç³»ç™½è¡€ç—…TKIè€è¯ä¸­çš„ä½œç”¨ï¼›USP13ç¨³å®šSOX9ä¿ƒè¿›è„‚è‚ªè‚åŠè‚ç™Œå¹²ç»†èƒè¡¨å‹ã€‚<br />
- è¡¨è§‚é—ä¼ è°ƒæ§ï¼šDNAç”²åŸºåŒ–ç¼–è¾‘åœ¨ä½“å†…ç ”ç©¶ï¼›Sp8å’ŒBrachyuryåœ¨èƒšèƒå¹²ç»†èƒåˆ†åŒ–ä¸­çš„ç»“åˆè°±ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- æ•´åˆå¤šç»„å­¦æ•°æ®ï¼ˆå…¨å¤–æ˜¾å­ç»„æµ‹åº+scRNA-seqï¼‰æ­ç¤ºç‰¹å®šç™Œç—‡æ ·æœ¬ç‰¹å¾ã€‚<br />
- ç©ºé—´è½¬å½•ç»„å­¦åˆ†æè¡°è€åµå·¢ã€‚</p>
<h3>ğŸ”¬ æœŸåˆŠæ–‡ç« </h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
æ­ç¤ºäº†ä¼‘çœ ç™Œç»†èƒï¼ˆDCCï¼‰çš„æœºåˆ¶ï¼Œä¸ºå…‹æœç™Œç—‡è½¬ç§»å’Œæ²»ç–—è€è¯æ€§æä¾›äº†æ–°è§†è§’ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- æ¢ç´¢Tetraspanin 13ï¼ˆTSPAN13ï¼‰åœ¨ä¹³è…ºç™Œå…ç–«é€ƒé€¸ä¸­çš„ä½œç”¨ï¼ŒåŠå…¶é€šè¿‡MHC-Ié™è§£å¢å¼ºå…ç–«æŠ‘åˆ¶çš„æœºåˆ¶ã€‚<br />
- ç ”ç©¶TET2å¤±æ´»åœ¨é€ è¡€ç³»ç»Ÿä¸­çš„ä½œç”¨ï¼Œä»¥åŠå…¶å¦‚ä½•å¢å¼ºå…ç–«æ£€æŸ¥ç‚¹é˜»æ–­ï¼ˆICBï¼‰çš„ç–—æ•ˆã€‚<br />
- å…³æ³¨EGFRçªå˜éå°ç»†èƒè‚ºç™Œï¼ˆNSCLCï¼‰ä¸­EGFR TKIè€è¯çš„æœºåˆ¶åŠæ–°å‹æ²»ç–—ç­–ç•¥ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- æ•´åˆåŸºå› ç»„ã€è¡¨å‹å’Œæ´»ç»†èƒæˆåƒåˆ†æï¼Œç”¨äºè§£ç ç™Œç—‡ä¼‘çœ ã€‚<br />
- åŠ¨æ€è‚¿ç˜¤å…ç–«è¡¨å‹åˆ†æï¼Œè¯„ä¼°æ–°è¾…åŠ©åŒ–ç–—è”åˆæ›²å¦¥ç å•æŠ—æ²»ç–—HER2é˜³æ€§ä¹³è…ºç™Œçš„ç–—æ•ˆã€‚</p>
<h3>ğŸ§ª åšå®¢æ›´æ–°</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
AIé©±åŠ¨çš„å¤šæ¨¡æ€å­¦ä¹ å·¥å…·CellWhispererå®ç°åŸºäºè‡ªç„¶è¯­è¨€çš„å•ç»†èƒåŸºå› è¡¨è¾¾æ•°æ®äº¤äº’æ¢ç´¢ï¼Œé©æ–°ç”Ÿç‰©æ•°æ®åˆ†ææ–¹å¼ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- åˆ©ç”¨AIå’ŒRNAæµ‹åºæ•°æ®ï¼Œå®ç°å•ç»†èƒåŸºå› è¡¨è¾¾çš„è‡ªç„¶è¯­è¨€äº¤äº’å¼æ¢ç´¢ã€‚<br />
- æ•´åˆåŠŸèƒ½æ€§è¯ç‰©æµ‹è¯•ã€RNAæµ‹åºä¸AIï¼Œä¸ºç™Œç—‡æ‚£è€…æä¾›ä¸ªæ€§åŒ–æ²»ç–—æ´å¯Ÿã€‚<br />
- GLP-1ç±»è¯ç‰©ï¼ˆå¦‚Ozempicã€Wegovyï¼‰å¯èƒ½æ˜¾è‘—é™ä½ç»“ç›´è‚ ç™Œæ‚£è€…æ­»äº¡ç‡ã€‚<br />
- å¼€å‘æ–°å‹æ™ºèƒ½è¯ç‰©ï¼Œé¶å‘å¹¶ç ´åç™Œç»†èƒä¾èµ–çš„ç‰¹å®šRNAç»“æ„ï¼Œè§¦å‘ç»†èƒè‡ªæ¯ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- åŸºäºAIçš„å¤šæ¨¡æ€å­¦ä¹ ï¼Œå®ç°ç”Ÿç‰©æ•°æ®ï¼ˆRNAæµ‹åºï¼‰ä¸è‡ªç„¶è¯­è¨€çš„èåˆã€‚<br />
- æ™ºèƒ½è¯ç‰©è®¾è®¡ï¼Œèƒ½è¯†åˆ«å¹¶ä½œç”¨äºRNAçš„ç‰¹å®šæŠ˜å ç»“æ„ã€‚</p>
            </div><h2>ğŸ“š åˆ†ç±»æµè§ˆ</h2>
<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ“° å…¬ä¼—å· (38æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>Early View | å—æ–¹åŒ»ç§‘å¤§å­¦ä½™å…‰åˆ›æ•™æˆå›¢é˜Ÿ ä¸¤ç§æµ‹åºå¹³å°åœ¨å°é¼ è„‘å’Œè‚ºå•ç»†èƒç©ºé—´è½¬å½•ç»„å­¦ç ”ç©¶ä¸­çš„æ¯”è¾ƒ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šYuLabSMU<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šæµ‹åºã€å•ç»†èƒã€ç©ºé—´è½¬å½•ç»„ã€ç©ºé—´ç»„å­¦ã€è½¬å½•ç»„<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šEarly View | å—æ–¹åŒ»ç§‘å¤§å­¦ä½™å…‰åˆ›æ•™æˆå›¢é˜Ÿ Illumina NovaSeq 6000 ä¸ GeneMind SURFSeq 5000å¹³å°åœ¨å°é¼ è„‘å’Œè‚ºå•ç»†èƒç©ºé—´è½¬å½•ç»„å­¦ç ”ç©¶ä¸­çš„æ¯”è¾ƒ<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzI5NjUyNzkxMg==&amp;mid=2247498252&amp;idx=1&amp;sn=1aa97994684c25c7ae3e4231a8033760" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> â­ <strong>æœ€æ–°14+ç”Ÿä¿¡ï¼Œé€šè¿‡å•ç»†èƒåˆ†æè¯†åˆ«HLA-DR +è‚¿ç˜¤ç»†èƒï¼Œå¹¶åˆ†æå…¶å¯¹ CD8+T ç»†èƒåŠé¢„åçš„å½±å“ï¼Œæ€è·¯æ–°é¢–ï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€å•ç»†èƒã€ç”Ÿä¿¡ã€é€šè·¯<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247503959&amp;idx=7&amp;sn=258dd76f48cf11330258c9f0cf0a7c5b" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> â­ <strong>æœ€æ–°14+ç”Ÿä¿¡ï¼Œå•ç»†èƒè¯†åˆ«PLAUR+ä¸­æ€§ç²’ç»†èƒå¡‘é€ å…ç–«æŠ‘åˆ¶å¾®ç¯å¢ƒï¼ŒæŠ‘åˆ¶PLAUR å¢å¼ºæŠ— PD1 ç–—æ•ˆã€‚é«˜åˆ†æ–‡ç« ç»å…¸æ€è·¯ï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå…ç–«ã€å…ç–«å¾®ç¯å¢ƒã€å•ç»†èƒã€ç”Ÿä¿¡<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247503959&amp;idx=5&amp;sn=ced8641c095eceaa9678fa06d1bf8ef4" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> â­ <strong>10.6åˆ†éè‚¿ç˜¤å¹²æ¹¿ç»“åˆç”Ÿä¿¡ï¼Œé¶å‘ CD177 + ä¸­æ€§ç²’ç»†èƒå‡è½»ç¼ºè¡€å†çŒæ³¨æŸä¼¤ã€‚é€‚åˆåŠ¨ç‰©å»ºæ¨¡æµ‹åºæ€è·¯ï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€æµ‹åºã€ç”Ÿä¿¡<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247503959&amp;idx=6&amp;sn=c75c9951e60626368294935ff46af274" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> â­ <strong>æœ€æ–°10åˆ†ç”Ÿä¿¡ï¼Œå•ç»†èƒ+ç©ºè½¬å¤šç»„å­¦è¿›è¡Œä¸­æ€§ç²’ç»†èƒäºšå‹åˆ†æï¼Œè¯†åˆ« CTCF+TANï¼Œé¶å‘CTCFæ”¹å–„å…ç–«æ²»ç–—ç–—æ•ˆï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå…ç–«ã€å•ç»†èƒã€ç”Ÿä¿¡<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247503959&amp;idx=1&amp;sn=98fdaa5daa63ceef5f7ad03d9d1e3575" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> â­ <strong>ã€ŠCellã€‹ï¼šç™Œç»†èƒç«Ÿç”¨â€œç—›æ„Ÿç¥ç»â€è¿œç¨‹æ“æ§å…ç–«ç³»ç»Ÿï¼é˜»æ–­æ­¤é€šè·¯ï¼Œå¯å®ç°æŠ—ç™Œä¸é•‡ç—›â€œåŒèµ¢â€</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡äºº<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå…ç–«ã€ç¥ç»ã€é€šè·¯<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šåœ¨è‚¿ç˜¤å…ç–«å­¦é¢†åŸŸï¼Œä¸ºä»€ä¹ˆå¼ºå¤§çš„å…ç–«ç³»ç»Ÿä¼šâ€œå¤±çµâ€ï¼Œä»»ç”±ç™Œç»†èƒç”Ÿé•¿ï¼Ÿ<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248461&amp;idx=1&amp;sn=1a190d284eabc1102646736924ac7090" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> <strong>æœ€æ–°7.5åˆ†ç”Ÿä¿¡ï¼Œå¤šç»„å­¦ç»“åˆæœºå™¨å­¦ä¹ ç­›é€‰è‚¥èƒ–ç›¸å…³çš„å…³é”®åŸºå› å¹¶éªŒè¯ï¼Œéè‚¿ç˜¤ç»å…¸æ€è·¯ï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šä¸œæ™“ç”Ÿç‰©<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€ç”Ÿä¿¡<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg2OTU2MzM2NA==&amp;mid=2247493008&amp;idx=1&amp;sn=18b8c9c83e0a9a10bad5e6735e65a7e1" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> <strong>åŸºå› æ³¨é‡Šä¿¡æ¯æ•´åˆæœ‰å›°éš¾ï¼Ÿæ‰¾GenomicFeaturesåŒ…å¸®ä½ æå®šæ‰€æœ‰åŸºå› ç»„æ³¨é‡Šéš¾é¢˜ï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šäº‘ç”Ÿä¿¡<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šåŸºå› ç»„ã€RåŒ…<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg5MDk3Mzg4OA==&amp;mid=2247498469&amp;idx=1&amp;sn=00dfdccbc88ce612a1d523e7dbe87f38" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> <strong>åˆšåˆšå‘è¡¨çš„8.9åˆ†ç”Ÿä¿¡ï¼Œé™¤äº†è¯†åˆ«æŸåŸºå› é˜³æ€§ç»†èƒï¼Œè¯†åˆ«æŸé€šè·¯/è¡¨å‹é˜³æ€§ç»†èƒä¹Ÿæ˜¯å‘æ–‡çš„å¥½æ€è·¯ï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šç”Ÿä¿¡ã€é€šè·¯<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247503959&amp;idx=3&amp;sn=a1374a34ca21fd2bdd5248cfdac4e615" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> <strong>33+ç”Ÿä¿¡ï¼Œ è¯†åˆ«ä»ç™Œå‰ç—…å˜åˆ°è‚¿ç˜¤ä¸åŒæ¶æ€§ç¨‹åº¦ç›¸å…³çš„ç»†èƒäºšå‹ï¼Œé’ˆå¯¹IL-33+å†…çš®ç»†èƒä¿ƒè¿›ç–¾ç—…è¿›å±•è¿›è¡Œå®éªŒéªŒè¯ï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€ç”Ÿä¿¡<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247503959&amp;idx=2&amp;sn=72e4d892b554597196b8b15bac2eeebb" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 28 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-å…¬ä¼—å·">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (35æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>GSE278674 é˜»æ–­ 6PGD å¯é™åˆ¶ç™Œç—‡ä¸­ç”±å…ˆå¤©å…ç–«ååº”é©±åŠ¨çš„å…ç–«æŠ‘åˆ¶</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€immuneã€regex:immuno(logy|therapy|suppression)<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Saeed Daneshmandi ; Eduardo C Gomez ; Jianmin Wang ; Hemn MohammadpourSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusThe pentose phosphate pathway (PPP) has always been relegated to the background of cellular metabolism, but our research identifies its unique and provocative influence on cell function, specifically in myeloid-derived suppressor cells (MDSCs). Weâ€™ve uncovered that 6-phosphogluconate dehydrogenase (6PGD), a rate limiting enzyme in this pathway, is not just a metabolic enzyme but a crucial determinant of MDSC behavior. While the IL-6/STAT3 axis propels 6PGD activity, it also empowers MDSCs to exert their immune-suppressive prowess. When we disrupt 6PGD â€“ either through genetic knockout or pharmacological inhibition â€“ an astonishing transformation occurs. The accumulation of 6-phosphogluconate (6PG) sets off a cascade involving JNK1-IRS-1 interaction and PI3K-AKT-pDRP1 signaling pathway, triggering mitochondrial fragmentation and dismantling oxidative phosphorylation (OXPHOS). This change in metabolism doesnâ€™t just disrupt MDSC function; it transforms it stimulatory, leading to a strong anti-tumor response and making anti-PD1 therapies much more effective. Our results suggest we need to completely rethink the role of the PPP in cell function, with 6PGD emerging as a key target that could change the future of cancer immunotherapy.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE278674" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> â­ <strong>GSE254498 æ•´åˆå…¨å¤–æ˜¾å­ç»„æµ‹åºå’Œå•ç»†èƒRNAæµ‹åºæ­ç¤ºäº†VHLç—…èƒŒæ™¯ä¸‹å‘ç”Ÿçš„ä¸€ä¾‹é€æ˜ç»†èƒè‚¾ç»†èƒç™Œæ ·æœ¬çš„ç‰¹å¾</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcarcinomaã€sequencingã€scRNA<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Wenhao Lu ; Tingwei Jin ; Xiaoxiang Yu ; Yixuan Liu ; Shengzhu Huang ; Zheng Wen ; Cheng Su ; Yu Ye ; Ziyan Huang ; Zengnan Mo ; Zhenyuan YuSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensClear cell renal cell carcinoma (ccRCC) arising in the setting of von Hippelâ€“Lindau (VHL) disease is a rare type of kidney cancer and features VHL germline mutation. This type of ccRCC is rarely characterised at the single-cell level. In this work, whole-exome sequencing and single-cell RNA sequencing (scRNA-seq) were conducted on one ccRCC sample with VHL disease. Integrating scRNA-seq and whole-exome sequencing data by the Seurat package, we determined the relationship between single-cell transcriptome features and gene mutations. Immunohistochemistry and immunofluorescence were performed on one VHL germline mutation ccRCC and six non-VHL germline mutation ccRCC samples. We revealed the gene expression characteristics of ccRCC with VHL germline mutation. The frameshift mutations in OBP2A and BCR1, and the elevated expression of COX7A1 were most specific characteristics of ccRCC tumor cells with VHL mutation. And the extensive infiltration of exhausted T cells was the characteristic of tumor microenvironment. In addition, we discovered the relationship between genetic mutations and immune checkpoints. This work highlights the single-cell transcriptome and DNA-level information of this rare ccRCC and will provide more genetic insights and references into this rare disease.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE254498" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> <strong>GSE281956 æ°§åŒ–æŠµæŠ— 1 (Oxr1) å¤±è°ƒä¿ƒè¿›æ…¢æ€§ç²’ç»†èƒç™½è¡€ç—…ä¸­çš„ TKI è€è¯æ€§å’Œæ€¥å˜æœŸã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šleukemiaã€resistance<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSeries Type : Genome variation profiling by high throughput sequencing ; Expression profiling by high throughput sequencing ; OtherOrganism : Homo sapiens ; Mus musculusThis SuperSeries is composed of the SubSeries listed below.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE281956" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> <strong>GSE281955 æ°§åŒ–æŠµæŠ— 1 (Oxr1) å¤±è°ƒä¿ƒè¿›æ…¢æ€§ç²’ç»†èƒç™½è¡€ç—…ä¸­çš„ TKI è€è¯æ€§å’Œæ€¥å˜æœŸ [æ•°æ®é›† 3]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šleukemiaã€resistance<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Weiqi Huang ; Elizabeth Eklund ; Priyam PatelSeries Type : OtherOrganism : Mus musculusTo unravel the intricate interplay among Oxr1, ROS-induced genetic changes, and dynamics influencing TKI resistance and CML progression<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE281955" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> <strong>GSE281954 æ°§åŒ–æŠµæŠ— 1 (Oxr1) å¤±è°ƒä¿ƒè¿›æ…¢æ€§ç²’ç»†èƒç™½è¡€ç—…ä¸­çš„ TKI è€è¯æ€§å’Œæ€¥å˜æœŸ [æ•°æ®é›† 2]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šleukemiaã€resistance<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Weiqi Huang ; Elizabeth Eklund ; Priyam PatelSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusTo unravel the intricate interplay among Oxr1, ROS-induced genetic changes, and dynamics influencing TKI resistance and CML progression<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE281954" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> <strong>GSE281856 æ°§åŒ–æŠµæŠ— 1 (Oxr1) å¤±è°ƒä¿ƒè¿›æ…¢æ€§ç²’ç»†èƒç™½è¡€ç—…ä¸­çš„ TKI è€è¯æ€§å’Œæ€¥å˜æœŸ [æ•°æ®é›† 1]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šleukemiaã€resistance<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Weiqi Huang ; Elizabeth Eklund ; Priyam PatelSeries Type : Genome variation profiling by high throughput sequencingOrganism : Mus musculusTo unravel the intricate interplay among Oxr1, ROS-induced genetic changes, and dynamics influencing TKI resistance and CML progression<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE281856" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> <strong>GSE280073 ä½“å†…DNAç”²åŸºåŒ–ç¼–è¾‘[ChIP-Seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šChIP-seqã€methylation<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Richard Pan ; Luis Flores ; X Shawn LiuSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Mus musculusDNA methylation is an epigenetic mechanism essential for orchestrating gene expression. Precise editing of DNA methylation has emerged as a new method to dissect its biological function in a DNA sequence specific manner with great potential to treat human diseases. However, applications of DNA methylation editing are largely in vitro. An experimental system to systematically investigate in vivo DNA methylation editing is needed to reveal its full therapeutic potential. We generated two transgenic mouse lines carrying an inducible dCas9-Dnmt3a or dCas9-Tet1 editor to enable cell-type specific methylation editing in vivo. We demonstrated that targeted methylation of the Psck9 promoter in the liver of dCas9-Dnmt3a mice reduced Psck9 expression and lowered plasma low-density lipoprotein cholesterol level to reduce the risk for cardiovascular diseases. Targeted demethylation of the Mecp2 promoter by dCas9-Tet1 reactivated Mecp2 expression from the inactive X chromosome in the brain of Mecp2 heterozygous Rett syndrome mice, suggesting a promising therapeutic approach for Rett syndrome and other X-linked diseases. Genome-wide sequencing analysis showed no detectable off-target at the transcriptional level in the methylation edited mice. These results demonstrate the feasibility and versatility of methylation editing in vivo, to explore DNA methylation in normal physiology and develop treatments for human diseases.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE280073" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> <strong>GSE280072 ä½“å†…DNAç”²åŸºåŒ–ç¼–è¾‘[RNA-Seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šRNA-seqã€methylation<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Richard Pan ; X Shawn LiuSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusDNA methylation is an epigenetic mechanism essential for orchestrating gene expression. Precise editing of DNA methylation has emerged as a new method to dissect its biological function in a DNA sequence specific manner with great potential to treat human diseases. However, applications of DNA methylation editing are largely in vitro. An experimental system to systematically investigate in vivo DNA methylation editing is needed to reveal its full therapeutic potential. We generated two transgenic mouse lines carrying an inducible dCas9-Dnmt3a or dCas9-Tet1 editor to enable cell-type specific methylation editing in vivo. We demonstrated that targeted methylation of the Psck9 promoter in the liver of dCas9-Dnmt3a mice reduced Psck9 expression and lowered plasma low-density lipoprotein cholesterol level to reduce the risk for cardiovascular diseases. Targeted demethylation of the Mecp2 promoter by dCas9-Tet1 reactivated Mecp2 expression from the inactive X chromosome in the brain of Mecp2 heterozygous Rett syndrome mice, suggesting a promising therapeutic approach for Rett syndrome and other X-linked diseases. Genome-wide sequencing analysis showed no detectable off-target at the transcriptional level in the methylation edited mice. These results demonstrate the feasibility and versatility of methylation editing in vivo, to explore DNA methylation in normal physiology and develop treatments for human diseases.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE280072" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> <strong>GSE274072 USP13 ç¨³å®š SOX9 ä»¥ä¿ƒè¿›ä»£è°¢åŠŸèƒ½éšœç¢ç›¸å…³çš„è„‚è‚ªè‚ç–¾ç—…å’Œè‚ç™Œå¹²ç»†èƒè¡¨å‹</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€metabolic<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Shao Na ; Zhang Lin ; Tan Xu ; Xiang Jingyi ; Xi Lei ; Idris Muhammad ; Shen Gufang ; Zhou Lu ; Ni Yuanshu ; Zhang Qiongyi ; Xu Feng ; Liu ChungangSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensDeregulation of SOX9 has been linked with metabolic diseases, self-renewal and cancer. SOX9, a master regulator of cell growth, can be regulated by a diverse set of Post-Translational Modifications (PTMs), including ubiquitylation. This study aims to elucidate the mechanisms that govern SOX9 protein stability that is mediated by the ubiquitin-proteasome system. Following a screen of the deubiquitinase library, SOX9 protein abundance was found to be regulated by ubiquitin-specific peptidase 13 (USP13) which deubiquitylates SOX9 and inhibits its protein degradation. Additionally, USP13 attenuates FBXW7- and KEAP1-mediated ubiquitination and degradation of SOX9 by directly binding to the SOX9 K2 domain, which contains a critical ubiquitination residue-K249. Genetic deletion or pharmacological inhibition of USP13 markedly decreases the metabolic dysfunction-associated fatty liver disease (MAFLD) development, the stemness capacity of liver cancer cells and enhances its chemo-sensitivity. Overexpression of exogenous SOX9 in USP13 deficient cells restored liver cancer cells self-renewal capacity and tumorigenesis. Clinical analyses revealed that the USP13-SOX9 axis is associated with poor prognosis in human hepatocellular carcinoma (HCC) patients. Therefore, pharmacological interventions targeting USP13 may have therapeutic potential for the treatment of HCC and MAFLD prevalent diseases.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE274072" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> <strong>GSE267315 è¡°è€äººç±»åµå·¢çš„ç©ºé—´è½¬å½•ç»„ç‰¹å¾</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šagingã€spatial<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Meiling Zhang ; Fanghao Guo ; Qing Zhang ; Qianhui Hu ; Di Sun ; Yongjian Ma ; Yanquan Li ; Mengxi Guo ; Haixia Ding ; Ying Guo ; Baicai Yang ; Songmao Li ; Ningxia Sun ; Yuxuan Zheng ; Wen LiSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensOvarian aging is a complex process that compromises fertility and elevates the risk of reproductive disorders. To elucidate its spatiotemporal dynamics, we integrated single-nucleus RNA sequencing and spatial transcriptomics to construct a comprehensive aging atlas of 12 human ovarian tissues spanning ages 12-54. Our analysis revealed aging-associated transcriptomic shifts, including impaired mitochondrial oxidative phosphorylation and reproductive structure development in aged human ovaries. We identified a novel endothelial cell (EDC) subtype, CLDN5âº blood EDCs, which exhibited unique functional specialization as (semi-professional) antigen-presenting cells. In contrast to other cell types that lost cell identity during aging, CLDN5âº blood EDCs displayed transcriptomic sensitivity to aging, characterized by enhanced antigen-presenting capabilities, and heightened inflammatory activity. Spatial mapping further uncovered immunoglobulin-expressing cell (IGHG1+/IGKC+) accumulation in the ovarian periphery, correlating with advancing age. Critically, aging disrupted global cellular connectivity while amplifying the DLK1:NOTCH3 axis between theca cells and CLDN5âº blood EDCs, which may contribute to the dysregulation of ovarian functions. The progressively upregulation of DLK1 indicates it as a robust biomarker of ovarian aging. This study significantly enhances our comprehension of the underlying mechanisms of human ovarian aging and concurrently pinpoints potential therapeutic avenues for addressing related disorders.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE267315" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 25 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-æ•°æ®å‰æ²¿">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ”¬ æœŸåˆŠæ–‡ç«  (7æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨7æ¡ï¼‰</h4>
<p><strong>1.</strong> <strong>è€é¾„åŒ–ç™Œç—‡å¹¸å­˜è€…äººç¾¤çš„å¿ƒè¡€ç®¡é£é™©ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šç™Œç—‡ã€å¿ƒè¡€ç®¡<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext:<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1988635595092635648/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> <strong>è§£ç ç™Œç—‡ä¼‘çœ ï¼šæ•´åˆåŸºå› ç»„ã€è¡¨å‹å’Œæ´»ç»†èƒæˆåƒåˆ†æï¼Œæ­ç¤ºéšè—çš„ç™Œç»†èƒåº“</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šç™Œç—‡ã€åŸºå› ç»„<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: è½¬ç§»æ˜¯ç™Œç—‡æ²»ç–—ä¸­æœ€å›°éš¾çš„éšœç¢ä¹‹ä¸€ï¼Œæ˜¯è®¸å¤šç™Œç—‡ç›¸å…³æ­»äº¡çš„åŸå› ã€‚äº†è§£é©±åŠ¨ç–¾ç—…è¿›å±•çš„æœºåˆ¶å¯¹äºæ”¹å–„æ‚£è€…é¢„åå’Œåˆ¶å®šæ›´æœ‰æ•ˆçš„æ²»ç–—ç­–ç•¥è‡³å…³é‡è¦ã€‚è¿™ç§ç°è±¡ä¼¼ä¹æ˜¯ç”±ä¼‘çœ ç™Œç»†èƒ ï¼ˆDCCï¼‰ å¼•èµ·çš„ï¼Œè¿™äº›ç»†èƒå¯ä»¥é•¿æ—¶é—´æŒç»­æœªè¢«å‘ç°ï¼Œè¿›å…¥éå¢æ®–ã€å†¬çœ æ ·çŠ¶æ€ï¼Œä»è€Œå¯¹ä¼ ç»Ÿç–—æ³•äº§ç”Ÿè€è¯æ€§å¹¶ä¿ƒè¿›å…ç–«é€ƒé¿ã€‚ç”±äº DCC ä½œä¸ºç¨€æœ‰ä¸”èƒ½é‡å—é™çš„äººç¾¤ï¼ŒåŠ ä¸Šå½“å‰åŒ»å­¦æˆåƒçš„å±€é™æ€§ï¼Œå®ƒä»¬å¾€å¾€é€ƒé¿æ—©æœŸå‘ç°ï¼Œé˜»ç¢äº†åŠæ—¶å¹²é¢„å’Œæœ‰æ•ˆçš„ä¸´åºŠç®¡ç†ã€‚å› æ­¤ï¼Œè¿«åˆ‡éœ€è¦å¼€å‘é«˜åˆ†è¾¨ç‡æ£€æµ‹ç³»ç»Ÿå¹¶è¯†åˆ«ç‰¹å®šçš„ DCC é¶å‘ç”Ÿç‰©æ ‡å¿—ç‰©ã€‚åœ¨è¿™é‡Œï¼ŒæŠ¥å‘Šäº†å¯¹å½“å‰å¯¹ DCC çš„ç†è§£çš„å…¨é¢æ¦‚è¿°ï¼Œé‡ç‚¹å…³æ³¨å…¶è¯†åˆ«å’Œè·Ÿè¸ªå®éªŒç­–ç•¥çš„æœ€æ–°è¿›å±•ï¼Œä»¥åŠç›®å‰æ­£åœ¨è¿›è¡Œçš„æ—¨åœ¨é¶å‘è¿™äº›éš¾ä»¥æ‰æ‘¸çš„ç»†èƒçš„ä¸´åºŠç ”ç©¶æ–¹æ³•ã€‚<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1988844182372986880/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> <strong>æ–°è¾…åŠ©åŒ–ç–—è”åˆæ›²å¦¥ç å•æŠ—æ²»ç–— HER2 é˜³æ€§ä¹³è…ºç™Œçš„åŠ¨æ€è‚¿ç˜¤å…ç–«è¡¨å‹å‰æ™¯</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€å…ç–«<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: å¯¹äº HER2 é˜³æ€§ä¹³è…ºç™Œï¼ˆBCï¼‰ï¼Œè¾¾åˆ°ç—…ç†å®Œå…¨ç¼“è§£ï¼ˆpCRï¼‰çš„æ‚£è€…é¢„è®¡å°†å…·æœ‰æ›´å¥½çš„ä¸´åºŠç»“æœã€‚éšç€æ–°è¾…åŠ©åŒ–ç–—ï¼ˆNACï¼‰è”åˆé¶å‘æ²»ç–—æ—¶ä»£çš„åˆ°æ¥ï¼ŒHER2 é˜³æ€§ BC çš„ pCR ç‡æ˜¾ç€æé«˜ï¼Œä½†å…¶ä¸­çº¦ 50%çš„æ‚£è€…ä»ç„¶å¯¹é¶å‘æ²»ç–—æ²¡æœ‰ååº”ã€‚è‚¿ç˜¤å¾®ç¯å¢ƒï¼ˆTMEï¼‰çš„åŠ¨æ€å˜åŒ–å¯èƒ½å¯¹ HER2 é˜³æ€§ BC çš„ pCR ç»“æœäº§ç”Ÿå…³é”®å½±å“ã€‚ç„¶è€Œï¼Œç›®å‰è¿˜æ²¡æœ‰ä¸æ²»ç–—æœŸé—´ç–—æ•ˆç›¸å…³çš„ç‰¹å¼‚æ€§å…ç–«è¡¨å‹ç ”ç©¶ã€‚æˆ‘ä»¬å¯¹ 28 ä¾‹ HER2 é˜³æ€§ BC æ‚£è€…è·å¾—çš„ 94 ä¸ª ROI è¿›è¡Œäº†å…¨é¢çš„ç©ºé—´è¡¨è¾¾åˆ†æï¼ŒåŒ…æ‹¬ä»–ä»¬çš„åˆå§‹è¯Šæ–­é˜¶æ®µå’Œæœ¯åçŠ¶æ€ã€‚åˆ©ç”¨ DSP æŠ€æœ¯ï¼Œæˆ‘ä»¬ç²¾ç¡®åœ°ç»˜åˆ¶å’Œé‡åŒ–äº†æ‚£è€…åœ¨è¿™äº›å…³é”®æ—¶é—´ç‚¹çš„ TMEã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œæˆ‘ä»¬å°†æ ‡æœ¬åˆ†ä¸ºå››ç»„ï¼šIM1ã€IM2ã€TM1 å’Œ TM2ã€‚ä»¥ CD4âº å¹¼ç¨š T ç»†èƒå’Œå¹¼ç¨š B ç»†èƒä¸ºç‰¹å¾çš„ IM1 å’Œ TM1 æ˜¾ç¤ºå‡ºè¾ƒé«˜çš„ pCR ç‡ï¼Œè€Œ IM2 å’Œ TM2 è¡¨ç°å‡ºè¾ƒä½çš„ç‡ã€‚æ­¤å¤–ï¼Œæœ¯åè¢«å½’ç±»ä¸º<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1988844183140544512/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> <strong>Tetraspanin 13 é€šè¿‡ä¿ƒè¿› MHC-I é™è§£å¢å¼ºä¹³è…ºç™Œçš„å…ç–«é€ƒé€¸</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå…ç–«<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: ä¸é«˜å…ç–«åŸæ€§æ¶æ€§è‚¿ç˜¤ç›¸æ¯”ï¼Œä¹³è…ºç™Œé€šå¸¸å…·æœ‰â€œå†·â€è‚¿ç˜¤å…ç–«å¾®ç¯å¢ƒï¼Œå…¶ç‰¹å¾æ˜¯å…ç–«ç»†èƒæµ¸æ¶¦ä½å’Œæ•ˆåº” T ç»†èƒæ¿€æ´»æœ‰é™ã€‚è¿™ç§å…ç–«æŠ‘åˆ¶è¡¨å‹å¯¹å…ç–«æ£€æŸ¥ç‚¹æŠ‘åˆ¶å‰‚å’Œå…¶ä»–å…ç–«æ²»ç–—æ–¹æ³•çš„ç–—æ•ˆæ„æˆäº†é‡å¤§éšœç¢ï¼Œå‡¸æ˜¾äº†ç¡®å®šé™åˆ¶æŠ—è‚¿ç˜¤å…ç–«æœºåˆ¶çš„å¿…è¦æ€§ã€‚åœ¨è¿™é¡¹ç ”ç©¶ä¸­ï¼Œæˆ‘ä»¬ç¡®å®šäº†å››è·¨è›‹ç™½ 13 ï¼ˆTSPAN13ï¼‰ åœ¨è°ƒèŠ‚è‚¿ç˜¤ç»†èƒè¡¨é¢ä¸»è¦ç»„ç»‡ç›¸å®¹æ€§å¤åˆç‰© I ç±» ï¼ˆMHC-Iï¼‰ è¡¨è¾¾ä¸­çš„ä½œç”¨ï¼Œè¿™æ˜¯ CD8+ T ç»†èƒè¯†åˆ«è‚¿ç˜¤ç‰¹å¼‚æ€§æŠ—åŸæ‰€å¿…éœ€çš„ã€‚åœ¨ä¹³è…ºç™Œæ‚£è€…æ ·æœ¬ä¸­ï¼ŒTSPAN13 è¡¨è¾¾ä¸ CD8âº T ç»†èƒæµ¸æ¶¦å‘ˆè´Ÿç›¸å…³ã€‚åœ¨æœºåˆ¶ä¸Šï¼ŒTSPAN13 é€šè¿‡å‹Ÿé›† STUB1 å¢å¼º MHC-I çš„æ³›ç´ åŒ–ï¼Œä»è€Œä¿ƒè¿›æº¶é…¶ä½“é™è§£ï¼Œæ˜¾è‘—é™ä½ç»†èƒè¡¨é¢ MHC-I æ°´å¹³ã€‚ä½“å¤–å’Œä½“å†…å®éªŒéƒ½è¡¨æ˜ï¼Œè‚¿ç˜¤ç»†èƒä¸­ TSPAN13 çš„ä¸¢å¤±æ˜¾ç€å¢å¼ºäº† CD8+ T ç»†èƒæ´»æ€§å¹¶æ”¹å–„äº†å¯¹è‚¿ç˜¤ç»†èƒçš„ç»†èƒæ¯’æ€§ã€‚æ­¤å¤–ï¼ŒæŠ‘åˆ¶ TSPAN13 è¡¨è¾¾æ˜¾ç€å¢åŠ äº†è‚¿ç˜¤å¯¹æŠ— PD-L1<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1988725015225413632/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> <strong>åœ¨é€ è¡€ TET2 å¤±æ´»çš„æƒ…å†µä¸‹ï¼Œå¯¹å…ç–«æ£€æŸ¥ç‚¹é˜»æ–­çš„ååº”å¢å¼º</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå…ç–«<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: ä½¿ TET2 å¤±æ´»çš„ä½“ç»†èƒçªå˜æ˜¯å…‹éš†é€ è¡€ ï¼ˆCHï¼‰ æœ€å¸¸è§çš„é©±åŠ¨å› ç´ ä¹‹ä¸€ã€‚TET2 å¤±æ´»ä¸å•æ ¸ç»†èƒè¡ç”Ÿç‚ç—‡å’Œæ”¹å–„åµŒåˆæŠ—åŸå—ä½“ T ç»†èƒåŠŸèƒ½æœ‰å…³ï¼Œè¡¨æ˜å®ƒä¹Ÿå¯èƒ½å½±å“å…ç–«æ²»ç–—ååº”ã€‚åœ¨è¿™é‡Œï¼Œæˆ‘ä»¬å‘ç°å°é¼ æ¨¡å‹ä¸­çš„é€ è¡€ Tet2 çªå˜å¢å¼ºäº†å…ç–«æ£€æŸ¥ç‚¹é˜»æ–­ ï¼ˆICBï¼‰ ååº”ï¼Œè¿™éœ€è¦åå™¬ç»†èƒã€CD4+ å’Œ CD8+ T ç»†èƒçš„è”åˆå­˜åœ¨ã€‚éšç€éª¨é«“æˆ– T ç»†èƒé™åˆ¶æ€§ Tet2 å¤±æ´»æˆ– 20% Tet2 çªå˜é€ è¡€çš„å°é¼ ï¼Œè¿™ç§æ•ˆæœä¼šæ¶ˆå¤±ã€‚ä»æœºåˆ¶ä¸Šè®²ï¼Œåœ¨ Tet2 çªå˜è‚¿ç˜¤æµ¸æ¶¦ç™½ç»†èƒ ï¼ˆTILï¼‰ ä¸­ï¼ŒICB ä¼˜å…ˆé™åˆ¶ä¸è‚¿ç˜¤è¿›å±•ç›¸å…³çš„ç»†èƒçŠ¶æ€ï¼ŒåŒæ—¶è¯±å¯¼æŠ—è‚¿ç˜¤çŠ¶æ€ã€‚Tet2 çªå˜å•æ ¸ç»†èƒæ¿€æ´»å…±åˆºæ¿€ç¨‹åºï¼Œè€Œ Tet2 çªå˜ T ç»†èƒè¡¨ç°å‡ºå¢å¼ºçš„ T ç»†èƒè®°å¿†ç‰¹å¾ï¼ŒåŒæ—¶å‡å°‘ç–²æƒ«å’Œè°ƒèŠ‚è¡¨å‹ã€‚ä¸´åºŠä¸Šï¼Œç»“ç›´è‚ ç™Œå’Œé»‘è‰²ç´ ç˜¤æ‚£è€…çš„ TET2 é©±åŠ¨çªå˜-CHï¼ˆTET2-CHï¼‰çš„è‚¿ç˜¤è¡¨ç°å‡ºå¢å¼ºçš„å…ç–«æµ¸æ¶¦ã€ç‚ç—‡å’Œ T ç»†èƒæ´»åŒ–ã€‚åœ¨æ¥å— ICB<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1988725040726781952/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> <strong>æ¢ç´¢ EGFR çªå˜ NSCLC ä¸­ EGFR TKI è€è¯çš„å‰æ™¯ - æœºåˆ¶å’Œä¸æ–­å‘å±•çš„æ²»ç–—æ–¹æ³•ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè€è¯<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: å¯¹ EGFR é…ªæ°¨é…¸æ¿€é…¶æŠ‘åˆ¶å‰‚ï¼ˆTKIsï¼‰çš„è€è¯æ€§ä»ç„¶æ˜¯ EGFR çªå˜éå°ç»†èƒè‚ºç™Œï¼ˆNSCLCï¼‰ä¸´åºŠæ²»ç–—çš„ä¸»è¦éšœç¢ã€‚å°½ç®¡ EGFR TKI çš„å¤šæ¬¡è¿­ä»£å…·æœ‰å˜é©æ€§çš„æ²»ç–—æ´»æ€§ï¼Œä»å„æ´›æ›¿å°¼å’Œå‰éæ›¿å°¼ç­‰ç¬¬ä¸€ä»£å¯é€†æŠ‘åˆ¶å‰‚åˆ°ç›®å‰æ ‡å‡†æŠ¤ç†çš„ç¬¬ä¸‰ä»£å…±ä»·æŠ‘åˆ¶å‰‚å¥¥å¸Œæ›¿å°¼ï¼Œä½†å¯¹è¿™äº›è¯ç‰©çš„åŸå‘æ€§æˆ–è·å¾—æ€§è€è¯æ€§ä¸å¯é¿å…åœ°é€šè¿‡ä¸åŒçš„æœºåˆ¶å‡ºç°ã€‚ç»“åˆåŒ–ç–—ã€æŠ—è¡€ç®¡ç”Ÿæˆå‰‚ã€åŒç‰¹å¼‚æ€§æŠ—ä½“æˆ–æŠ—ä½“-è¯ç‰©å¶è”ç‰©çš„è”åˆç–—æ³•çš„å‡ºç°å¢åŠ äº†ä¸´åºŠè·ç›Šï¼Œä½†å¼•å…¥äº†æ–°çš„è€è¯è¡¨å‹ï¼Œå¼ºè°ƒäº†æ²»ç–—å‹åŠ›ä¸‹è‚¿ç˜¤è¿›åŒ–çš„åŠ¨æ€å¯å¡‘æ€§å’Œå¤æ‚æ€§ã€‚åœ¨æœ¬ç»¼è¿°ä¸­ï¼Œæˆ‘ä»¬å…¨é¢ç»¼åˆäº†å¯¹ç¬¬ä¸‰ä»£ EGFR TKIs è€è¯çš„åˆ†å­æœºåˆ¶ï¼Œæè¿°äº†ç”Ÿç‰©æ ‡å¿—ç‰©å¼•å¯¼å’Œç”Ÿç‰©æ ‡å¿—ç‰©éé€‰æ‹©çš„æ²»ç–—ç­–ç•¥æ¥å…‹æœè¿™äº›æœºåˆ¶ï¼Œå¹¶è®¨è®ºäº†é€šè¿‡æ—©æœŸåº”ç”¨è”åˆç–—æ³•æ¥é¢„é˜²è€è¯æ€§çš„æ–°æ–¹æ³•ã€‚æˆ‘ä»¬å¼ºè°ƒäº†æ²»ç–—è€è¯æ€§ä»æ”¾å°„å­¦ç›‘æµ‹åˆ°åˆ†å­ç›‘æµ‹çš„èŒƒå¼è½¬å˜ï¼Œå¹¶æ¢è®¨äº†å¾ªç¯è‚¿ç˜¤ DNA åˆ†æã€äººå·¥æ™ºèƒ½å’Œå¤šç»„å­¦çš„è¿›æ­¥å¦‚ä½•ä¿ƒè¿›é€‚åº”æ€§æ²»ç–—ç­–ç•¥ã€‚éšç€æ²»ç–—æ ¼<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1988726423458787328/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> <strong>ç™Œç—‡ä¸­çš„ä¸­æ€§ç²’ç»†èƒç»†èƒå¤–é™·é˜±</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šç™Œç—‡<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext:<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1988832524158218240/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§ª åšå®¢æ›´æ–° (4æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨4æ¡ï¼‰</h4>
<p><strong>1.</strong> <strong>CellWhispererâ€”â€”å¤šæ¨¡æ€å­¦ä¹ æ”¯æŒåŸºäºèŠå¤©æ–¹å¼çš„å•ç»†èƒæ•°æ®æ¢ç´¢</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šsingle-cell<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šCellWhisperer uses AI and RNA sequencing data to let researchers explore single-cell gene expression through natural-language chats, making complex biological data easier to understand and analyze...<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/cellwhisperer-multimodal-learning-enables-chat-based-exploration-of-single-cell-data/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> <strong>åŸºäºç”Ÿç‰©å­¦ã€DNA/RNA å’Œäººå·¥æ™ºèƒ½çš„ä¸ªæ€§åŒ–ç™Œç—‡è¯Šæ–­ç»“æœï¼Œå¹³å‡ 10 å¤©å†…å³å¯äº¤ä»˜ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancer<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šFirst Ascent Biomedical integrates functional drug testing, RNA sequencing, and AI to deliver personalized cancer treatment insights in just ten days, helping oncologists act before cancer progresses...<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/personalized-cancer-insights-grounded-in-biology-dna-rna-ai-delivered-in-an-average-of-10-days/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> <strong>Wegovy å’Œ Ozempic ä¸ç™Œç—‡æ­»äº¡ç‡å¤§å¹…ä¸‹é™æœ‰å…³</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancer<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šGLP-1 drugs such as Ozempic and Wegovy may extend the lives of colon cancer patients, according to a major UC San Diego study. Patients on the medications had less than half the mortality rate of non-users. Researchers suspect the drugsâ€™ anti-inflammatory and metabolic effects contribute to improved outcomes. Theyâ€™re now calling for clinical trials to test whether these findings reflect a true anti-cancer mechanism.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2025/11/251112011810.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> <strong>æ™ºèƒ½è¯ç‰©é¶å‘ç™Œç»†èƒä¸­éšè—çš„RNAå¼±ç‚¹</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancer<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šResearchers have designed a smart drug that hunts down and breaks a little-known RNA that cancer cells depend on. The drug recognizes a unique fold in the RNA and triggers the cell to destroy it. Tests showed that removing this RNA slows cancer growth. The approach could lead to new treatments that attack cancer at its most fundamental level.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2025/11/251112111033.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
</div>
</details>

<h2>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</h2>
<table class="keywords-table">
<thead>
<tr>
<th>å…³é”®è¯</th>
<th>å‡ºç°æ¬¡æ•°</th>
</tr>
</thead>
<tbody>
<tr>
<td>å…ç–«</td>
<td>11</td>
</tr>
<tr>
<td>å•ç»†èƒ</td>
<td>10</td>
</tr>
<tr>
<td>cancer</td>
<td>10</td>
</tr>
<tr>
<td>ç”Ÿä¿¡</td>
<td>9</td>
</tr>
<tr>
<td>è‚¿ç˜¤</td>
<td>8</td>
</tr>
<tr>
<td>é€šè·¯</td>
<td>5</td>
</tr>
<tr>
<td>ç¥ç»</td>
<td>5</td>
</tr>
<tr>
<td>leukemia</td>
<td>5</td>
</tr>
<tr>
<td>RNA-seq</td>
<td>4</td>
</tr>
<tr>
<td>ç™Œç—‡</td>
<td>4</td>
</tr>
<tr>
<td>resistance</td>
<td>4</td>
</tr>
<tr>
<td>sequencing</td>
<td>3</td>
</tr>
<tr>
<td>ChIP-seq</td>
<td>3</td>
</tr>
<tr>
<td>ç©ºé—´ç»„å­¦</td>
<td>3</td>
</tr>
<tr>
<td>methylation</td>
<td>3</td>
</tr>
<tr>
<td>ä»£è°¢</td>
<td>2</td>
</tr>
<tr>
<td>åŸºå› ç»„</td>
<td>2</td>
</tr>
<tr>
<td>æµ‹åº</td>
<td>2</td>
</tr>
<tr>
<td>single-cell</td>
<td>2</td>
</tr>
<tr>
<td>immune</td>
<td>2</td>
</tr>
</tbody>
</table>
<hr />
<h2>ğŸ“ æ›´å¤šå†…å®¹</h2>
<details>
<summary><a name="æ›´å¤š-å…¬ä¼—å·"></a>ğŸ“° å…¬ä¼—å· å…¶ä»–å†…å®¹ (28æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzI5ODI0NzM2OQ==&amp;mid=2247491574&amp;idx=1&amp;sn=e12a8543d86765ac6cb47fa10cf3c456" target="_blank" rel="noopener noreferrer">ä»é›¶å¼€å§‹å­¦ä¹ å•ç»†èƒå…ç–«ç»„åº“ï¼ˆä¸€ï¼‰ï¼šåŸºç¡€æ¦‚å¿µè½»æ¾æ˜æ™°ï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkzODIxMDY5NQ==&amp;mid=2247507103&amp;idx=2&amp;sn=5a8929fc6672e7ac9f87973846fa1fbb" target="_blank" rel="noopener noreferrer">æ–‡çŒ®åˆ†äº« | ã€Natureé‡ç£…å‘å¸ƒã€‘ç©ºé—´ä¸‰ç»„å­¦å…¨æ™¯å¼ç»˜åˆ¶å¤§è„‘å‘è‚²ä¸ç¥ç»ç‚ç—‡åŠ¨æ€å›¾è°±</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg2NTE1MzU4NQ==&amp;mid=2247523404&amp;idx=1&amp;sn=648e40253e672bd1f6645458422a1e6e" target="_blank" rel="noopener noreferrer">ç”¨ R è¯­è¨€ç©è½¬è‚¿ç˜¤è€è¯é¢„æµ‹ï¼šä»æ•°æ®åˆ°æ¨¡å‹ï¼Œä¸€ç¯‡æå®šï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkxOTI0Mjc3Mw==&amp;mid=2247496703&amp;idx=1&amp;sn=de3d9310d2c963f71f7eb1aecbe476e7" target="_blank" rel="noopener noreferrer">ä»£è°¢ç‰©å¯¹å·¨å™¬ç»†èƒæåŒ–åŠè‚¿ç˜¤çš„å½±å“</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzU1MDk1NTY5MA==&amp;mid=2247540954&amp;idx=1&amp;sn=2e7251ed3cd9b8ac3f0c69dae7e52b84" target="_blank" rel="noopener noreferrer">çº¿ä¸Šè®²åº§é¢„å‘Š | é¡¶åˆŠæ€ç»´Â·å‰æ²¿æ´è§â€”â€”å•ç»†èƒä¸ç©ºé—´ç»„å­¦åœ¨åŒ»å­¦åŠæ¤ç‰©ç ”ç©¶ä¸­çš„åˆ›æ–°åº”ç”¨</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzI1Njk4ODE0MQ==&amp;mid=2247533627&amp;idx=1&amp;sn=b792c36ae5dd857f6bceece37e6ad69c" target="_blank" rel="noopener noreferrer">å•ç»†èƒå¤šç»„å­¦åˆ†æAIPèƒ°è…ºç‚æ‚£è€…å¹´é¾„ç›¸å…³Bç»†èƒï¼ˆABCï¼‰å…‹éš†æ‰©å¢ç‰¹å¼‚æ€§</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkwMjYyMDA1OA==&amp;mid=2247489214&amp;idx=1&amp;sn=70e72a1a94533041ad7695ee26368d1d" target="_blank" rel="noopener noreferrer">å…ç–«ç»„åº“åˆ†æå­¦ä¹ -Tç»†èƒå—ä½“(ä¸€ï¼‰</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzYyNDMwNjg3Nw==&amp;mid=2247484034&amp;idx=1&amp;sn=f02a67cbbaefb9c59d9d770dfa0e3892" target="_blank" rel="noopener noreferrer">è¯¦è§£ï¼šè‚ é“-è‚è„è½´çš„ä»£è°¢è°ƒæ§æœºåˆ¶</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkyMTI1MTYxNA==&amp;mid=2247519777&amp;idx=1&amp;sn=1216b2124d39fa48cd26393bc18e9279" target="_blank" rel="noopener noreferrer">å¯¼å¸ˆè®©æˆ‘åšä¸ªå•ç»†èƒè¯¾é¢˜ï¼Œæˆ‘ç›´æ¥æ‹’äº†</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247503959&amp;idx=8&amp;sn=c7f13672c884d03e40e133498b3e04d3" target="_blank" rel="noopener noreferrer">åˆšåˆšå‘è¡¨çš„14+ç”Ÿä¿¡åˆ†æï¼Œè¯†åˆ«MMP11+æˆçº¤ç»´ç»†èƒè¿›è¡Œåˆ†æå’ŒéªŒè¯ï¼Œæœ¬æ–‡æ€è·¯æ–°é¢–ï¼Œå€¼å¾—è®¤çœŸå­¦ä¹ æ¨¡ä»¿ï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247503959&amp;idx=4&amp;sn=0fdcf03d6048c404051b88c95de509cb" target="_blank" rel="noopener noreferrer">ä»‹ç»ä¸¤ä¸ªç”Ÿä¿¡çƒ­ç‚¹å‘æ–‡æ€è·¯</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkwMzY2NjkwNg==&amp;mid=2247495530&amp;idx=1&amp;sn=d6558e06f00a4b5f544f095b7d23e14b" target="_blank" rel="noopener noreferrer">Nat Biotechnol |å¤©å‘ï¼Œä»»ä½•å’ŒAIæŒ‚é’©çš„éƒ½æ˜¯ç‹ç‚¸ï¼Œä»¥åå•ç»†èƒæœ€éš¾çš„è§£é‡Šéƒ¨åˆ†ï¼Œè¿˜æœ‰å•¥éš¾çš„</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkyNzcxMjEyMg==&amp;mid=2247497913&amp;idx=1&amp;sn=c3059ac4769547f4ff1ba47690e8598c" target="_blank" rel="noopener noreferrer">IF:5.7ï¼ŒæˆåŒ»å¤§è¿™ã€èŒç¾¤-è‚ -è„‘è½´+TLR4/NF-ÎºBé€šè·¯ã€‘æ€è·¯ï¼Œå°±æ˜¯å…¸å‹çš„æ ‡ä¹¦æ¨¡æ¿</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzI4ODc5MDI5NA==&amp;mid=2247503469&amp;idx=1&amp;sn=d3e0dd971776f7825a7e6cc4baf80688" target="_blank" rel="noopener noreferrer">ã€Šç™Œç»†èƒã€‹ï¼šåè½¬äº†ï¼ç§‘å­¦å®¶é¦–æ¬¡å‘ç°ï¼Œä¿ƒç™Œçš„TET2çªå˜å…‹éš†é€ è¡€ï¼Œç«Ÿä¼šä¿ƒè¿›å·¨å™¬ç»†èƒå‘ˆé€’æŠ—åŸï¼Œå¢å¼ºå…ç–«æ²»ç–—æ•ˆæœ</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkzNzY2NDgyOQ==&amp;mid=2247493289&amp;idx=1&amp;sn=12b6bf67a17eb960ee84a0c35dda040f" target="_blank" rel="noopener noreferrer">å‘å±•è½¨è¿¹çš„å½¢çŠ¶ï¼šç®€å•çš„å¤šé¡¹å¼æ›²çº¿-é€æ­¥å¼•å…¥å®Œå…¨éçº¿æ€§çš„è¶‹åŠ¿å»ºæ¨¡</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzAxMDkxODM1Ng==&amp;mid=2247546918&amp;idx=1&amp;sn=44e912011085ca09ab9f929f0cf393b1" target="_blank" rel="noopener noreferrer">scATAC-seqä¸­å¸¸è§çš„è´¨æ§å›¾</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkzODIxMDY5NQ==&amp;mid=2247507103&amp;idx=1&amp;sn=d2da71f4a5c1e8e8f7f315e9f1ec5dc1" target="_blank" rel="noopener noreferrer">AlphaDIAï¼šæ‰“é€šDIAè›‹ç™½è´¨ç»„å­¦åˆ†æçš„â€œä»»ç£äºŒè„‰â€</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248461&amp;idx=7&amp;sn=186a8b8e7feb5ffba57e91c7f6050ccb" target="_blank" rel="noopener noreferrer">ç™»æƒå¨æœŸåˆŠï¼èšç„¦é£Ÿç®¡é³ç™Œç ”ç©¶ï¼šä¸­å›½åŒ»å­¦ç§‘å­¦é™¢è‚¿ç˜¤åŒ»é™¢å›¢é˜Ÿå‘ç°Notchä¿¡å·ä¿ƒè¡€ç®¡ç”Ÿæˆå…³é”®æœºåˆ¶</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248461&amp;idx=6&amp;sn=984c1d9fa00b52cf5bc6691c51957f8a" target="_blank" rel="noopener noreferrer">è™šæ‹Ÿæ„ŸæŸ“èƒ½è§¦å‘å…ç–«ååº”ï¼Ÿã€Šnature neuroscienceã€‹æ­ç¤ºå¤§è„‘çš„ç¥å¥‡é˜²å¾¡æœºåˆ¶</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248461&amp;idx=5&amp;sn=e3f8967a46a6bd1e8cdf29ff08f8e850" target="_blank" rel="noopener noreferrer">åˆ©ç”¨ç”Ÿå­˜é¢„åæ¨¡å‹é¢„æµ‹ç™Œç—‡æ‚£è€…ç»“å±€ï¼šä»æ•°æ®åˆ†æåˆ°æ¨¡å‹è§£è¯»</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248461&amp;idx=4&amp;sn=ac2032ec8e6c7a783b2fd8c1ff84d739" target="_blank" rel="noopener noreferrer">é¡¶åˆŠæŒç»­å‘åŠ›ï¼Œæ¢ç´¢å¤§è„‘ç¨³æ€çš„å¥¥ç§˜ï¼šå°èƒ¶è´¨ç»†èƒä¸ç¥ç»å…ƒçš„å¯¹è¯</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248461&amp;idx=2&amp;sn=977cc06e7914514e6636017e1e914919" target="_blank" rel="noopener noreferrer">ç™»é¡¶topçº§æœŸåˆŠï¼GWAS+å•ç»†èƒåˆ†æè§£å¯†ç–¾ç—…æœºåˆ¶ï¼Œè¿™æ³¢æ€è·¯å¿…é¡»å­¦ï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzUxMzk5MjY5NA==&amp;mid=2247649935&amp;idx=6&amp;sn=fa8068580202375d595b040c45ed002a" target="_blank" rel="noopener noreferrer">Neuronï¼šä¸­å›½ç§‘å­¦é™¢è„‘æ™ºå“è¶Šä¸­å¿ƒæœä¹…æ—ç»„å‘ç°å¤§è„‘è¡€æµå…¨å±€è°ƒé…çš„ç¥ç»æœºåˆ¶</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzUxMzk5MjY5NA==&amp;mid=2247649935&amp;idx=4&amp;sn=efa41dc81a39784174818204a32349ac" target="_blank" rel="noopener noreferrer">Cellï¼šæ›¹ç¿/è–›å¤©/é™ˆè´ºå›¢é˜Ÿé˜é‡Š 5-HT1A å—ä½“ä¿¡å·é€šè·¯é€‰æ‹©æ€§æœºåˆ¶å¹¶è®¾è®¡å‡ºæ–°å‹å¿«é€ŸæŠ—æŠ‘éƒè¯ç‰©åˆ†å­</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzUxMzk5MjY5NA==&amp;mid=2247649935&amp;idx=3&amp;sn=769af18c80110f79a156ae1ec27886cd" target="_blank" rel="noopener noreferrer">Natureï¼šè¥¿æ¹–å¤§å­¦é‚¹è´»é¾™å›¢é˜Ÿåˆä½œå¼€å‘å¾®ç±³çº§è›‹ç™½è´¨ç»„å­¦æˆåƒæ–°æŠ€æœ¯</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzUxMzk5MjY5NA==&amp;mid=2247649935&amp;idx=2&amp;sn=4f8b20d100756549306b3fc45961df1f" target="_blank" rel="noopener noreferrer">Nature åè¿˜æœ‰æ–°çªç ´ï¼Ÿæƒå¨æœŸåˆŠè¯¦è§£ç¥ç»ç–¾ç—…ç”Ÿç‰©æ ‡å¿—ç‰©ç ”ç©¶æ€è·¯</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg5NjgxNjkwOA==&amp;mid=2247503133&amp;idx=1&amp;sn=6c3dbabebc2473ce6004529384fb11c7" target="_blank" rel="noopener noreferrer">å¤šç»„å­¦ | Nat.Genet. | åˆ©ç”¨å¤šç»„å­¦æ•°æ®é¢„æµ‹éå°ç»†èƒè‚ºç™Œå…ç–«æ²»ç–—æ•ˆæœçš„ç©ºé—´ç‰¹å¾</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkxODY4NDEwMA==&amp;mid=2247489832&amp;idx=1&amp;sn=076c4f1616c8ca1489a058ddcb8672e9" target="_blank" rel="noopener noreferrer">ç”·æ€§è¡°è€çš„æ ‡å¿—:1è‡­2é«˜3å¤§2å°</a></li>
</ul>
</div>
</details>

<details>
<summary><a name="æ›´å¤š-æ•°æ®å‰æ²¿"></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (25æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309417" target="_blank" rel="noopener noreferrer">GSE309417 å…”è½¯éª¨è†œç»„ç»‡çš„ RNA-seq åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE301148" target="_blank" rel="noopener noreferrer">GSE301148 åŒæ—¶é¶å‘ KRAS å’Œ CDK4 å¯ååŒè¯±å¯¼èƒ°è…ºç™Œç»†èƒæŒä¹…ç”Ÿé•¿åœæ» [AsPC-1_RNA_Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE301146" target="_blank" rel="noopener noreferrer">GSE301146 åŒæ—¶é¶å‘ KRAS å’Œ CDK4 å¯ååŒè¯±å¯¼èƒ°è…ºç™Œç»†èƒæŒä¹…ç”Ÿé•¿åœæ» [51T-2D_RNA_Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE272333" target="_blank" rel="noopener noreferrer">GSE272333 æ„å»ºåŸºäºæ¿€å…‰æ•è·æ˜¾å¾®åˆ‡å‰²çš„äººç±»ç”Ÿé•¿æœŸæ¯›å›Šè½¬å½•ç»„å›¾è°±</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE248519" target="_blank" rel="noopener noreferrer">GSE248519 ZKSCAN3 é€šè¿‡ä¸Šè°ƒ HSPB1 ä¿ƒè¿›åµå·¢ç™Œç»†èƒå¢æ®–</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304997" target="_blank" rel="noopener noreferrer">GSE304997 CDK4/6æŠ‘åˆ¶é€šè¿‡Rbä¾èµ–æ€§æŸ“è‰²è´¨å’Œè½¬å½•ç»„é‡å¡‘é‡ç¼–ç¨‹ä¹³è…ºç™Œå…ç–«è‚½ç»„</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304675" target="_blank" rel="noopener noreferrer">GSE304675 é€†è½¬çš„äººç±»iPSCè¡ç”Ÿè‚æ˜ŸçŠ¶ç»†èƒå¼‚è´¨æ€§çš„å•ç»†èƒåˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293442" target="_blank" rel="noopener noreferrer">GSE293442 ä½“å¤–è¡ç”ŸNMPçš„Brachyury (T) ChIP-seqåˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291742" target="_blank" rel="noopener noreferrer">GSE291742 Sp8åœ¨åˆ†åŒ–å°é¼ èƒšèƒå¹²ç»†èƒä¸­çš„å…¨åŸºå› ç»„ç»“åˆè°±</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287955" target="_blank" rel="noopener noreferrer">GSE287955 CDK4/6æŠ‘åˆ¶é€šè¿‡Rbä¾èµ–æ€§æŸ“è‰²è´¨å’Œè½¬å½•ç»„é‡å¡‘é‡ç¼–ç¨‹ä¹³è…ºç™Œå…ç–«è‚½ç»„</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE252659" target="_blank" rel="noopener noreferrer">GSE252659 å¯¹å¯¹ç…§ç»„å’Œ Sp5/8 åŒæ•²é™¤æˆ– Wnt3a æ•²é™¤èƒšèƒçš„ E8.25 åéƒ¨ç»„ç»‡ +2 ä½“èŠ‚è¿›è¡Œæ‰¹é‡ RNA æµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304892" target="_blank" rel="noopener noreferrer">GSE304892 p210æ¿€é…¶ç»“æ„åŸŸçªå˜æ£€æµ‹</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302709" target="_blank" rel="noopener noreferrer">GSE302709 ç”Ÿç‰©å·¥ç¨‹ç»†èƒå¤–å›Šæ³¡å…±é€’é€ PD-L1 å’Œ miR-27a-3p ååŒé‡ç¼–ç¨‹ T ç»†èƒä»¥æ²»ç–—ç‚ç—‡æ€§è‚ ç—… [RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302696" target="_blank" rel="noopener noreferrer">GSE302696 ç”Ÿç‰©å·¥ç¨‹ç»†èƒå¤–å›Šæ³¡å…±é€’é€ PD-L1 å’Œ miR-27a-3p ååŒé‡ç¼–ç¨‹ T ç»†èƒä»¥æ²»ç–—ç‚ç—‡æ€§è‚ ç—… [scRNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE280074" target="_blank" rel="noopener noreferrer">GSE280074 ä½“å†…DNAç”²åŸºåŒ–ç¼–è¾‘[WGBS]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE250483" target="_blank" rel="noopener noreferrer">GSE250483 é€šè¿‡æ•´åˆçŸ­è¯»é•¿å’Œé•¿è¯»é•¿RNAæµ‹åºå‘ç°æ–°å‹ç¯çŠ¶RNA</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE306484" target="_blank" rel="noopener noreferrer">GSE306484 åˆ©ç”¨ ReSisTrace è°±ç³»è¿½è¸ªæŠ€æœ¯æ­ç¤ºæ€¥æ€§é«“ç³»ç™½è¡€ç—…ä¸­å¯¹ FLT3 æŠ‘åˆ¶å‰‚çš„é¢„è‡´æ•å› å­</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298330" target="_blank" rel="noopener noreferrer">GSE298330 ArpC5çªå˜å°é¼ å’Œå¯¹ç…§å°é¼ å›è‚ å…ç–«ç»†èƒå•ç»†èƒæ°´å¹³çš„åŸºå› è¡¨è¾¾è°±</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290177" target="_blank" rel="noopener noreferrer">GSE290177 çƒ­ä¼‘å…‹è½¬å½•å› å­ (HSF) ä»‹å¯¼æ¤ç‰©ä¸­çƒ­è¯±å¯¼æŸ“è‰²è´¨åŠ¨æ€çš„å¤šå±‚è°ƒæ§ [ATAC-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290176" target="_blank" rel="noopener noreferrer">GSE290176 çƒ­ä¼‘å…‹è½¬å½•å› å­ (HSF) ä»‹å¯¼æ¤ç‰©ä¸­çƒ­è¯±å¯¼æŸ“è‰²è´¨åŠ¨æ€çš„å¤šå±‚è°ƒæ§ [RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE285103" target="_blank" rel="noopener noreferrer">åˆ©ç”¨ GSâ€‹â€‹E285103 CENH3-ChIP-seq å¯¹ Chamaelirium luteum è¿›è¡Œæµ‹åºï¼Œä»¥ç¡®å®šå…¶å¤§ç€ä¸ç²’çš„å¤§å°å’Œåºåˆ—ç»„æˆã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE285102" target="_blank" rel="noopener noreferrer">åˆ©ç”¨GSE285102 ATAC-seqæµ‹åºæ•°æ®ï¼Œå¯¹é»„è¤æ‹Ÿå±‚å­”é›€è—»ï¼ˆChamaelirium luteumï¼‰è¿›è¡Œæµ‹åºï¼Œä»¥ç¡®å®šå…¶å¯åŠæŸ“è‰²è´¨åŒºåŸŸã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE248682" target="_blank" rel="noopener noreferrer">GSE248682 æ–°ç”Ÿ RNA åˆ†ææ­ç¤ºäº†åŸºå› ç»„èŒƒå›´å†…çš„é«˜æ•ˆé‡å¤èµ·å§‹è°ƒæ§ç»†èŒåŸºå› è½¬å½•</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE247772" target="_blank" rel="noopener noreferrer">GSE247772 è‡´æ­»æ€§å·¨å‹å¹¼è™«åŸºå› å®¶æ—åœ¨çš®è‚¤è¡¨çš®ä¸­å‘æŒ¥æŠ‘ç™ŒåŸºå› çš„ä½œç”¨</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE239990" target="_blank" rel="noopener noreferrer">GSE239990 çœŸçš®è„‚è‚ªç»†èƒé€šè¿‡ä»£è°¢é€šè®¯æ¿€æ´»æ¯›å›Šå¹²ç»†èƒ</a></li>
</ul>
</div>
</details>

<hr />
<p><em>ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2025-11-13 21:36</em><br />
<em>ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ</em></p>
    </div>
</body>
</html>